- Global Operation
- Contract Manufacturing
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result. Daunorubicin hydrochloride may also inhibit polymerase
activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin hydrochloride possesses
an antitumor effect against a wide spectrum of animal tumors, either grafted or spontaneous.
Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunobin for Injection 20 mg: Each box containing 1 vial in plastic tray.